Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

The Future of Real-World Evidence

THE XTALKS BLOG

Electronic Medical Records

Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients.

Share this!

March 14, 2017 | by The Knowledgent Team

The availability of anonymized, real-world clinical data sources (e.g. Medical Claims, Lab Results, and EMRs) is driving a paradigm shift in the understanding of the efficacy of medical treatments. Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients. Some of the most common RWE Analytics Use Cases include:

  • Comparing treatment effectiveness
  • Negotiating drug prices based on outcomes
  • Increasing patient medication adherence

However, for many conditions requiring specialty clinical care, the era of obtaining RWE insights from insurance claims is drawing to a close. Life Sciences companies are developing treatments for increasingly smaller subsets of disease populations, expanding the information needed to define populations and characterize their course of illness. The data elements required to establish these patient populations and to demonstrate that new treatments improve patient outcomes relative to the usual care will require a new breed of technologies and tools. Fortunately, recent advancements made in Silicon Valley are shaping the path for the future of Real-World Evidence, where evidence generation is specialty-focused, efficient, and democratized.



  • With the emergence of the Internet of Things (IOT), future RWE data sources will become more diverse and comprehensive in measuring various aspects of patient health
  • Blockchain technology, which debuted with Bitcoin and is now being further developed for healthcare, will enable the secure storage of patient health data and the direct transmission of anonymized data to Pharmaceutical companies
  • Continued progress in Cognitive Computing will advance the analytic pipeline, enabling deeper insights to be gained from the stores of RWE data

Real-World Evidence

Modern advancements in data and analytics technologies represent an important milestone in evidence generation. Knowledgent’s experience in RWE research substantiates the notion that adoption of these newer technologies and management of exponentially growing real-world data sources will inevitably require the Life Sciences industry to standardize to a Common Data Model (CDM) to enable interoperable, transparent evidence generation ecosystem. In the future, data providers, technology providers, researchers, and other RWE stakeholders will increase the value of analytics in Life Sciences innovation by plugging into a standardized RWE infrastructure that supports interoperability between rich and diverse data sources and analytic tools.

To learn more about real-world evidence, register for the upcoming webinar hosted by Knowledgent and SAS.



Keywords: Real-World Evidence, Clinical Data Sources, Electronic Medical Records


| NEXT ARTICLE | MORE BLOG POSTS | NEWS | VIDEOS | POLLS & QUIZZES | WEBINARS |

 

        Share this with your colleagues!




        READ THESE NEXT
        The Future of Real-World Evidence

        March 14, 2017 - Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients.


        Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity

        March 7, 2017 - Once a drug begins to reach the end of its patent period, it’s vulnerable to being scooped up by generic drugmakers who seek to develop a copycat version of the medication. Authorized generics are identical to the company’s branded product in terms of both active and inactive excipient ingredients; the only thing missing is the brand name and packaging that comes along with it.


        Five Ways to Optimize Capsule Filling Production

        March 2, 2017 - If your product’s ideal formulation is a capsule, there a few things you should consider before manufacturing.

        LEAVE A COMMENT
         
          
        THE XTALKS VITALS WEBINAR PRODUCTION TIPS BLOG

        Top Ten Webinar Production Tips of 2016

        REGISTER FOR THESE WEBINARS

        How to Improve the Speed and Efficiency of Your Clinical Trials


        High Performance Computing for High Content Screening - A Case Study


        The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


        Treatment of Psoriasis: Improvements Through Clinical Trials


        Copyright © 2016-2017 Honeycomb Worldwide Inc.